ATE227309T1 - Analoge des glucagon ähnlichen peptides -2 - Google Patents

Analoge des glucagon ähnlichen peptides -2

Info

Publication number
ATE227309T1
ATE227309T1 AT97916280T AT97916280T ATE227309T1 AT E227309 T1 ATE227309 T1 AT E227309T1 AT 97916280 T AT97916280 T AT 97916280T AT 97916280 T AT97916280 T AT 97916280T AT E227309 T1 ATE227309 T1 AT E227309T1
Authority
AT
Austria
Prior art keywords
glucagon
peptide
analogue
analogs
synthesis
Prior art date
Application number
AT97916280T
Other languages
English (en)
Inventor
Daniel J Drucker
Anna E Crivici
Martin Sumner-Smith
Original Assignee
Ontario Inc 1149336
Allelix Biopharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24530501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE227309(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ontario Inc 1149336, Allelix Biopharma filed Critical Ontario Inc 1149336
Application granted granted Critical
Publication of ATE227309T1 publication Critical patent/ATE227309T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT97916280T 1996-04-12 1997-04-11 Analoge des glucagon ähnlichen peptides -2 ATE227309T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63127396A 1996-04-12 1996-04-12
PCT/CA1997/000252 WO1997039031A1 (en) 1996-04-12 1997-04-11 Glucagon-like peptide-2 analogs

Publications (1)

Publication Number Publication Date
ATE227309T1 true ATE227309T1 (de) 2002-11-15

Family

ID=24530501

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01129072T ATE478892T1 (de) 1996-04-12 1997-04-11 Dem glukagon ähnliches peptid-2
AT97916280T ATE227309T1 (de) 1996-04-12 1997-04-11 Analoge des glucagon ähnlichen peptides -2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01129072T ATE478892T1 (de) 1996-04-12 1997-04-11 Dem glukagon ähnliches peptid-2

Country Status (16)

Country Link
EP (5) EP1231219B1 (de)
JP (3) JP4148994B2 (de)
CN (1) CN1268640C (de)
AT (2) ATE478892T1 (de)
AU (1) AU733857B2 (de)
BR (1) BRPI9708566B8 (de)
CA (1) CA2251576C (de)
DE (2) DE69716905T2 (de)
DK (2) DK0906338T3 (de)
ES (2) ES2188929T3 (de)
FR (1) FR13C0013I2 (de)
HK (1) HK1050204B (de)
LU (1) LU92153I2 (de)
NZ (1) NZ332281A (de)
PT (2) PT906338E (de)
WO (1) WO1997039031A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
EP1231219B1 (de) 1996-04-12 2010-08-25 1149336 Ontario Inc. Dem Glukagon ähnliches Peptid-2
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
CA2289652C (en) * 1997-05-16 2012-02-28 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
EP1060192A2 (de) * 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivate mit einem helixgehalt über 25%, die partiell strukturierte mizellenartige aggregate bilden
AU7421598A (en) * 1998-05-11 1999-11-29 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
EP1970072A1 (de) 2000-09-18 2008-09-17 Sanos Bioscience A/S Verwendung von GLP-2-Peptiden zur Behandlung von Hyperparathyreodismus
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
DE602004031927D1 (de) 2003-02-04 2011-05-05 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
ATE437181T1 (de) * 2003-08-21 2009-08-15 Novo Nordisk As Reinigung glucagonähnlicher peptide
ES2642214T3 (es) 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
EP1809318B1 (de) 2004-11-01 2013-06-12 NPS Pharmaceuticals, Inc. Behandlung von patienten mit kurzdarmsyndrom und dickdarmkontinuität
UA95235C2 (en) † 2005-05-04 2011-07-25 Зииланд Фарма А/С Glucagon-like-peptide-2 (glp-2) analogues
CN100418983C (zh) * 2005-05-11 2008-09-17 中国药科大学 人胰高血糖素相关肽-2类似物
CN101573376B (zh) 2006-11-08 2013-11-06 西兰制药公司 选择性胰高血糖素样肽-2（glp-2）类似物
CN101824087A (zh) * 2009-03-05 2010-09-08 连云港恒邦医药科技有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
EP2311486A1 (de) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 zur Verwendung in der Dünndarm- und Muskelwiederherstellung
EP2314616A1 (de) * 2009-10-23 2011-04-27 Ferring B.V. GLP-2-Peptid-Agonisten
KR20120101037A (ko) * 2009-10-30 2012-09-12 오츠카 가가쿠 가부시키가이샤 항원성 ｇｌｐ?１ 아날로그의 당쇄 부가체
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US20130157954A1 (en) * 2010-05-11 2013-06-20 Nps Pharmaceuticals, Inc. Methods for treatment or prophylaxis of kidney or liver dysfunction
EP2694083A2 (de) 2011-04-01 2014-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptide und pharmazeutische zusammensetzungen zur nasalen verabreichung für die behandlung von patienten mit angstzuständen und schlafstörungen
CN102924589B (zh) * 2011-08-11 2016-08-24 中肽生化有限公司 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
CN103159848B (zh) * 2013-01-06 2015-11-25 中国人民解放军第四军医大学 人胰高血糖素样肽-2二串体蛋白及其制备方法
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
EP3526242A1 (de) 2016-10-12 2019-08-21 University of Copenhagen Duale peptidagonisten von gipr und glp2r
EP3551651B1 (de) 2016-12-09 2024-03-06 Zealand Pharma A/S Acylierte glp-1/glp-2 duale agoniste
IL299864B2 (en) 2017-06-16 2024-06-01 Zealand Pharma As Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
EP3628682A1 (de) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
EP3628683A1 (de) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
CA3129576A1 (en) 2019-02-11 2020-08-20 Opko Biologics Ltd. Long-acting glp-2 analogs
SG11202111311WA (en) 2019-06-14 2021-12-30 Zealand Pharma As Pharmaceutical parenteral composition of dual glp1/2 agonist
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
EP4126004A1 (de) 2020-03-30 2023-02-08 Zealand Pharma A/S Agonistenkombination
CA3240750A1 (en) * 2021-12-17 2023-06-22 Bainan Biotech Aps Peptide dual agonists of gipr and glp2r

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
JP2961045B2 (ja) 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
DE69740176D1 (de) 1996-03-01 2011-05-26 Novo Nordisk As Appetithemmendes Peptid, Zusammensetzung und Verwendung
EP1231219B1 (de) 1996-04-12 2010-08-25 1149336 Ontario Inc. Dem Glukagon ähnliches Peptid-2
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity

Also Published As

Publication number Publication date
ATE478892T1 (de) 2010-09-15
HK1147761A1 (en) 2011-08-19
HK1033324A1 (en) 2001-08-24
EP0906338B1 (de) 2002-11-06
JP5019466B2 (ja) 2012-09-05
EP2218734B1 (de) 2013-06-05
JP4149497B2 (ja) 2008-09-10
DK0906338T3 (da) 2003-03-03
JP2008184465A (ja) 2008-08-14
EP2218734A2 (de) 2010-08-18
PT906338E (pt) 2003-03-31
FR13C0013I2 (fr) 2013-08-16
AU733857B2 (en) 2001-05-31
FR13C0013I1 (de) 2013-05-04
JP2000511881A (ja) 2000-09-12
HK1050204A1 (en) 2003-06-13
DE69716905D1 (de) 2002-12-12
EP2009024A1 (de) 2008-12-31
HK1050204B (en) 2011-09-23
PT1231219E (pt) 2010-11-30
CA2251576C (en) 2012-08-21
NZ332281A (en) 2000-03-27
ES2351661T3 (es) 2011-02-09
EP1231219A1 (de) 2002-08-14
CA2251576A1 (en) 1997-10-23
BRPI9708566A (pt) 2000-01-04
ES2188929T3 (es) 2003-07-01
EP1231219B1 (de) 2010-08-25
CN1268640C (zh) 2006-08-09
DE69716905T2 (de) 2003-07-24
CN1244872A (zh) 2000-02-16
EP2275438A1 (de) 2011-01-19
BR9708566B1 (pt) 2012-09-04
EP2218734A3 (de) 2010-10-13
EP0906338A1 (de) 1999-04-07
WO1997039031A1 (en) 1997-10-23
DE60142885D1 (de) 2010-10-07
JP2007204491A (ja) 2007-08-16
DK1231219T3 (da) 2010-12-20
LU92153I2 (fr) 2013-04-19
JP4148994B2 (ja) 2008-09-10
BRPI9708566B8 (pt) 2022-01-18
AU2500297A (en) 1997-11-07

Similar Documents

Publication Publication Date Title
ATE227309T1 (de) Analoge des glucagon ähnlichen peptides -2
NO944644D0 (no) Fremstilling av 3,4,4-trisubstituert-piperidinyl-N-alkylkarboksylater og mellomprodukter
DE69638057D1 (de) Glucagon ähnliche peptide-2 und ihre therapeutische verwendung
HUT64298A (en) Method for producing 9-amino-7-(substituted)-6-demethyl-6-desoxy-0tetracycline derivatives and medical preparatives containing them
BR9206027A (pt) Análogo de oligonucleotídio, composto de subunidade de oligonucleotídeo, processo para preparar tal composto, processo para modular a produção ou atividade de uma proteína, e, processo para tratar um organismo tendo uma doença distinta pela produção indesejada de uma proteína
HUT68963A (en) Novel 4-arylpiperazines and 4-arylpiperidines, pharmaceutical compositions comprising them and the proces for producing thereof
ES2164633T3 (es) Genes vegetales sinteticos y procedimiento para su preparacion.
HU9700886D0 (en) New intermediates and process for producing them
NO920193L (no) Fremgangsmaate for fremstilling av aspartam fra et diketopiperazin og nye mellomprodukter og derivater derfor
AU7880494A (en) 5-methyluridine process for large-scale preparation of 2',3'-didehydro-3'-deoxythymidine (d4T)
ATE236139T1 (de) Verfahren zur herstellung von 2-chlor-5- chlomethyl-thiazol-derivaten
ATE281432T1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
GR920100570A (el) Παραγωγα 3(2η)-πυριδαζινονης και μεθοδος για την παρασκευη τους.
GR3002841T3 (en) 4-(1,2,5,6-tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines
ES2144698T3 (es) Procedimiento para preparar un derivado de biciclohexano.
CA2030732A1 (fr) Nouveaux derives du thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant
NO20002600D0 (no) Mellomprodukter og fremgangsmÕter for anvendelse ved semisyntesen av paclitaxel og analoger
YU2292A (sh) Antibakterijska sredstva
DE59610819D1 (de) Arzneistoffe zur selektiven bekämpfung von tumorgewebe
ATE196292T1 (de) Zwischenprodukte um 2-imidazolin-5onederivate herzustellen.
HU9203928D0 (en) 6-sulfonyl-substituted 3-hydroxi-chromane derivatives and pharmaceutical preparatives containing them
FR2395033A1 (fr) Produits s'opposant aux mauvaises odeurs, renfermant notamment un groupe cyclohexenyle
AU3854097A (en) Thienylcyclohexane derivatives for thienylcyclohexyl synthesis
NZ332245A (en) Substituted benzo-oxazolol carboxylic acid derivatives, process for their production and medicaments containing them
HU910463D0 (en) Process for the production of medical preparation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0906338

Country of ref document: EP

EEFA Change of the company name